Investor Presentaiton

Targeted Protein Degradation and Cell Therapy: Two differentiated platforms for optimizing therapies for patients Targeted Protein Degradation Molecular glue Target protein Molecular glue molecule Hetero- bifunctional Target protein ADC degrader Matching modality to mechanism Cell Therapy Autologous Next-generation Single CAR binder Multiple other KO/KI TCR KO Dual CAR binder E3 ligase E3 ligase Cysteine residue Invention of high- quality therapeutics that match a modality Dual CAR binder MHC-I KO MHC-II • Drug-Linker KO to a molecular mechanism of action CELMOD LDD Ill Bristol Myers Squibb™ CELMOD ADC These two platforms unlock novel targets and mechanisms to efficiently deliver INDS with the potential to improve the lives of patients Allogeneic, iPSC-derived Not for Product Promotional Use 41

View entire presentation